Savara Inc. (NASDAQ:SVRA) Receives Average Rating of “Moderate Buy” from Analysts

Savara Inc. (NASDAQ:SVRA) has earned a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $9.1250.

A number of research firms have weighed in on SVRA. Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. HC Wainwright reiterated a “buy” rating on shares of Savara in a research note on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research note on Tuesday, April 21st. Oppenheimer began coverage on Savara in a research note on Friday, April 24th. They set an “outperform” rating and a $11.00 price objective for the company. Finally, William Blair set a $10.00 price objective on Savara in a research note on Monday, March 16th.

Key Stories Impacting Savara

Here are the key news stories impacting Savara this week:

• Positive Sentiment: Savara presented new biomarker data from the IMPALA-2 Phase 3 trial, adding to evidence supporting molgramostim’s potential in aPAP. Article Title
• Positive Sentiment: The company also announced new exercise capacity data from the same Phase 3 program, which may strengthen the case for clinical benefit and market opportunity. Article Title
• Positive Sentiment: Savara presented long-term efficacy and safety data from the ongoing IMPALA-2 open-label extension, potentially reducing investor concerns about durability and tolerability of the treatment. Article Title
• Negative Sentiment: HC Wainwright trimmed several future earnings estimates for Savara, including FY2026 through FY2030, signaling a slightly more cautious outlook on profitability and commercialization timing.

Hedge Funds Weigh In On Savara

Institutional investors have recently modified their holdings of the stock. Swedbank AB increased its stake in shares of Savara by 54.5% in the 4th quarter. Swedbank AB now owns 850,000 shares of the company’s stock valued at $5,126,000 after purchasing an additional 300,000 shares in the last quarter. F m Investments LLC increased its stake in shares of Savara by 56.5% in the 4th quarter. F m Investments LLC now owns 678,813 shares of the company’s stock valued at $4,093,000 after purchasing an additional 245,100 shares in the last quarter. Rosalind Advisors Inc. increased its stake in shares of Savara by 50.7% in the 3rd quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company’s stock valued at $14,280,000 after purchasing an additional 1,345,056 shares in the last quarter. Nan Fung Trinity HK Ltd. purchased a new position in shares of Savara in the 4th quarter valued at about $10,182,000. Finally, Vanguard Group Inc. increased its stake in shares of Savara by 20.8% in the 4th quarter. Vanguard Group Inc. now owns 10,041,647 shares of the company’s stock valued at $60,551,000 after purchasing an additional 1,728,453 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Stock Performance

Shares of SVRA stock opened at $5.08 on Friday. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -9.07 and a beta of 0.28. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47. The business has a fifty day moving average of $5.32 and a 200 day moving average of $5.50. Savara has a 1 year low of $1.89 and a 1 year high of $7.01.

Savara (NASDAQ:SVRA) last issued its earnings results on Wednesday, May 13th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). As a group, research analysts expect that Savara will post -0.58 earnings per share for the current year.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.